Impax Laboratories, Inc.
http://www.impaxlabs.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Impax Laboratories, Inc.
Gilead, Teva Document Disclosures Helped Sway Jury In Rare Pay-For-Delay Trial
Teva’s counsel notes a key factor in the jury's finding that Gilead’s patent settlement with Teva did not include a reverse payment to delay entry of Truvada and Atripla generics. A second trial will proceed on claims a collaboration agreement between Gilead and Janssen was anticompetitive.
Liquid Biopsy Revolutionizing Cancer Care, But Costs Continue To Inhibit Global Potential
Liquid biopsy represents potential advantages over traditional approaches to cancer surveillance, treatment selection and recurrence monitoring. But one size does not fit all, requiring tailored solutions for less developed markets.
Liquid Biopsy Revolutionizing Cancer Care, But Costs Continue To Inhibit Global Potential
Liquid biopsy represents potential advantages over traditional approaches to cancer surveillance, treatment selection and recurrence monitoring. But one size does not fit all, requiring tailored solutions for less developed markets.
Illumina Settles BGI Patent Battles For $325M
The settlement resolves a total of eight lawsuits between the companies on genetic sequencing technology and alleged antitrust violations.
Company Information
- Industry
-
Pharmaceuticals
- Generic Drugs
- Specialty Pharmaceuticals
-
Drug Delivery
- Controlled Release
- Other Names / Subsidiaries
-
- Amedra Pharmaceuticals LLC
- CorePharma LLC
- Impax Generics
- Impax Specialty Pharma
- Lineage Therapeutics Inc.
- Tower Holdings, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice